

NEWS RELEASE

Solasia Announces Launch of Darvias® in Japan

TOKYO, JAPAN, August 22nd 2022 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiko Wakumoto).

This Press Release is the same announces as that has released on Aug 17th,2022 in Japanese.

###

(Contact)

Solasia Pharma K.K.

Toyokazu Ohata, Public Relations and Investor Relations

Tel: +81 3 5843 8046 (TOKYO)

info@solasia.co.jp